Market Research Logo

Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Pipeline Review, H2 2018

Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Pipeline Review, H2 2018

Summary

Connective Tissue Growth


Introduction
Global Markets Direct Report Coverage
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Overview
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Companies Involved in Therapeutics Development
BLR Bio LLC
FibroGen Inc
OliX Pharmaceuticals Inc
ProMetic Life Sciences Inc
RXi Pharmaceuticals Corp
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Drug Profiles
BLR-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLR-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target SOD2 and CTGF for Radiation Toxicity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IB-DMD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLX-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLX-301D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLX-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pamrevlumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBI-4050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXI-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Dormant Products
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Discontinued Products
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Product Development Milestones
Featured News & Press Releases
Aug 10, 2018: Prometic announces the publication of PBI-4050's antifibrotic activity in liver diseases in journal of pharmacology and experimental therapeutics
Aug 07, 2018: Prometic receives rare pediatric disease designation from U.S. FDA for small molecule drug candidate PBI-4050
Aug 02, 2018: RXi Pharmaceuticals granted patents for sd-rxRNA technology strengthening intellectual property estate in Europe and Japan
Aug 01, 2018: RXi Pharmaceuticals announces positive results from phase 1/2 trial with RXI-109 For retinal scarring
Jun 03, 2018: FibroGen Presents Clinical Results of Pamrevlumab Treatment in Patients with Locally Advanced Unresectable Pancreatic Cancer at ASCO 2018 Annual Meeting
May 29, 2018: OliX Pharmaceuticals receives Clinical Trial Authorization in the UK to initiate Phase I study with OLX10010, an anti-scar RNAi therapeutics
May 22, 2018: Prometic presents new clinical data on PBI-4050 for the treatment of idiopathic pulmonary fibrosis
May 21, 2018: FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2018
May 08, 2018: RXi Pharmaceuticals Bolsters Strength of Dermatology Intellectual Property Estate Following Granting of Patent From USPTO
Apr 12, 2018: Prometic Presents New PBI-4050 Clinical Data From Ongoing Alstrom Syndrome Phase 2 Trial
Apr 04, 2018: RXi Pharmaceuticals to Present an Update on its Hypertrophic Dermal Scars Drug Candidate RXI-109 at the International Investigative Dermatology Conference
Mar 28, 2018: Prometic Reports Positive Clinical Data From Ongoing PBI-4050 Phase 2 Study in Alstrom Syndrome Patients
Mar 01, 2018: Fibrogen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer
Feb 16, 2018: Prometic Announces Publication of PBI-4050's Novel Antifibrotic Mechanism of Action in American Journal of Pathology
Jan 29, 2018: Prometics PBI-4050: Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis (IPF) Finalized
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by BLR Bio LLC, H2 2018
Pipeline by FibroGen Inc, H2 2018
Pipeline by OliX Pharmaceuticals Inc, H2 2018
Pipeline by ProMetic Life Sciences Inc, H2 2018
Pipeline by RXi Pharmaceuticals Corp, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Discontinued Products, H2 2018
List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report